Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Dynamic imaging of individual remyelination profiles in multiple sclerosis.
US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Saccadic intrusions: review and update.
Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Pediatric multiple sclerosis.
Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial.
The INCAT disability score: A critical analysis of its measurement properties.
Teva to present positive data for glatiramer acetate 40 mg/1 ml given three times weekly for relapsing-remitting MS
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.
Clinical profile of malay children with optic neuritis.
Disease-modifying treatments for progressive multiple sclerosis.
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Physiopathological Roles of p2x Receptors in the Central Nervous System.
Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Risk factors for rare diseases can be risky to define: PML and natalizumab.
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of multiple sclerosis
Overcoming barriers in progressive multiple sclerosis research.
The multiple sclerosis rating scale, revised (MSRS-R): Development, refinement, and psychometric validation using an online community.
Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection.
Guillain-Barré syndrome-like-onset neurosarcoidosis positive for immunoglobulin G anti-N-acetylgalactosaminyl-GD1a antibody.

Pages